Quantcast
Last updated on April 18, 2014 at 21:21 EDT

New Standards, Guidelines Fuel a Growing Mandate for Capnography

September 20, 2011

Anesthesia Patient Safety Foundation (APSF) recommends capnography for reducing opioid-induced postoperative respiratory depression

Jerusalem/Needham, MA (PRWEB) September 20, 2011

Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN), the creator of the Integrated Pulmonary Index̢Ң, one of the Smart Capnography̢Ң family of decision-support solutions, today heralded recently released recommendations by the Anesthesia Patient Safety Foundation (APSF) to reduce opioid-induced postoperative respiratory depression through the use of capnography.1

Addressing what it terms the âœserious patient safety riskâ of postoperative opioid-induced respiratory depression, the APSF calls for the immediate adoption of:

  • Continuous ventilation monitoring for all postoperative patients, as monitoring only patients deemed at risk by preoperative screening âœis likely to miss respiratory depression in patients without risk factors.â
  • Monitoring for adequacy of ventilation and airflow in all patients receiving supplemental oxygen.

The APSF also observes that it âœis aware of hospital system experiences that support the effectiveness of alternative continuous respiratory monitoring technologies, such as capnography, in lieu of pulse oximetry.â

The APSF joins several leading patient safety and medical organizations that have recently incorporated capnography, the noninvasive monitoring of carbon dioxide in exhaled breath (etCO2) to assess a patientâs ventilatory status, into their standards or guidelines.

  • The American Society of Anesthesiologists (ASA) issued updated standards for anesthetic monitoring, effective July 1, 2011, requiring capnography for patients receiving general anesthesia, during moderate or deep procedural sedation, and while breathing with an endotracheal tube or laryngeal mask inserted.2
  • The 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care stress the critical importance of continuous waveform capnography to confirm and monitor endotracheal tube placement, assess the quality of CPR, and detect return of spontaneous circulation (ROSC).3
  • The American Association for Respiratory Care (AARC) also issued updated guidelines recommending capnography/capnometry for verification of artificial airway placement; assessment of pulmonary circulation and respiratory status; and optimization of mechanical ventilation.4
  • In May 2011, the Association of Anaesthetists of Great Britain & Ireland (AAGBI) released updated recommendations for the use of capnography outside the operating room, stating that continuous capnography monitoring should be used for all anesthetized patients, regardless of the airway device used or the location of the patient; all patients whose trachea is intubated, regardless of the location of the patient; all patients undergoing moderate or deep sedation, and available wherever any patients undergoing anesthesia or moderate or deep sedation are recovered; and all patients undergoing advanced life support.5

âœThe increasing recognition and use of capnography will enable healthcare professionals to improve safety for their patients,â Gerry Feldman said. âœAs the market leader and the company that has been the pioneer for capnography for the past decade, Oridion is well positioned to meet the growing demand for this patient safety technology and fulfill our mission to improve medicine and save lives.â

For further Oridion information please contact:

Investors, Analysts, Financial Media

Alan Adler, Chairman and Chief Executive Officer

Walter Tabachnik, Chief Financial Officer

Elena Gerberg, Investor Relations

e-mail                    investor(at)oridion(dot)com

website                 http://www.oridion.com

phone                    +972 2 589 9159

Trade Media, Customers

Greg Spratt, Director of Clinical Marketing

e-mail: greg.spratt (at)oridion(dot)com

Marla Marom, Director of Marketing Communications

e-mail: marla.marom(at)oridion(dot)com

About Oridion

Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patientâs breath. These products provide effective and proven airway management and are used in various clinical environments, including procedural sedation, pain management, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patientsâ ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking. The words “estimate” “project” “intend” “expect” “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company’s products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company’s products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company’s proprietary technology. The Company does not assure any obligation to update the forward looking information contained in this press release.    

1 Stoelting R and Overdyk F. Anesthesia Patient Safety Foundation, Conclusions and Recommendations from June 08, 2011 Conference on Electronic Monitoring Strategies to Detect Drug-Induced Postoperative Respiratory Depression. Accessed August 25, 2011 at http://www.apsf.org/announcements.php?id=7.

2 ASA Standards for Basic Anesthetic Monitoring, Committee of Origin: Standards and Practice Parameters (Approved by the ASA House of Del¬egates on October 21, 1986, and last amended on October 20, 2010 with an effective date of July 1, 2011) . Accessed March 21, 2011 at http://www.asahq.org/…/Standards%20Guidelines%20Stmts/Basic%20Anesthetic%20Monitor¬ing%202011.ashx

3 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC). Highlights of the 2010 American Heart Association Guidelines for CPR and ECC.

4 Capnography/Capnometry During Mechanical Ventilation: 2011. AARC Clinical Practice Guideline. Accessed June 20, 2011 at http://www.rcjournal.com/cpgs/pdf/04.11.0503.pdf.

5 The Use of Capnography Outside the Operating Theatre. Updated Statement from the Association of Anaesthetists of Great Britain & Ireland (AAGBI) May 2011. Accessed August 25, 2011 at http://www.aagbi.org/sites/default/files/Capnographyaagbi090711AJH%5B1%5D_1.pdf.

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/9/prweb8799788.htm


Source: prweb